Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

Trial Profile

A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELVN-001 (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms CML; ENABLE
  • Sponsors Enliven Therapeutics

Most Recent Events

  • 03 Jul 2025 Planned number of patients changed from 180 to 200.
  • 13 Jun 2025 Result (n=53) presented in the Enliven Therapeutics Media Release
  • 13 Jun 2025 According to an Enliven Therapeutics media release, company presented positive data from the Phase 1 ENABLE clinical trial in an oral presentation at the European Hematology Association (EHA) 2025 Congress taking place June 12-15 in Milan, Italy, and virtually.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top